Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

G&A expenses for the year ended December 31, 2024 were $6.7 million, compared to $7.3 million for the same period in 2023, ...

Evercore ISI initiated coverage of Summit Therapeutics (SMMT) with an Outperform rating and $30 price target The firm sees lead asset, ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Barclays 27th Annual Global Healthcare Conference Call March 12, 2025 2:00 PM ETCompany ParticipantsBrian Evanko - Chief ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

On March 4, 2025, filings revealed that CEO Stephane Bancel purchased 160,314 shares of MRNA stock between $31.04 and $31.53, ...

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...